We are live on ! Find out more
EVFM

Evofem Biosciences, Inc. Common Stock

Delisted

EVFM was delisted on the 10th of August, 2022.

103 hedge funds and large institutions have $74.5M invested in Evofem Biosciences, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 31 increasing their positions, 19 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

72% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 18

63% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 19

11% more funds holding

Funds holding: 93103 (+10)

7% less capital invested

Capital invested by funds: $80M → $74.5M (-$5.48M)

14% less call options, than puts

Call options by funds: $1.05M | Put options by funds: $1.22M

Holders
103
Holders Change
+10
Holders Change %
+10.75%
% of All Funds
1.81%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
31
Increased
31
Reduced
19
Closed
18
Calls
$1.05M
Puts
$1.22M
Net Calls
-$167K
Net Calls Change
-$676K

EVFM Hedge Fund Activity: Q1 2021 in Review

103 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Evofem Biosciences, Inc. Common Stock (EVFM) for Q1 2021, worth a combined $74.5M — down 6.8% from $80M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new EVFM positions and 18 closed out — a net gain of 13 holders — while 31 added to existing stakes and 19 trimmed.

The largest buyer was Maven Securities, opening a new position worth an estimated $8.33M. The largest seller was Invesco, cutting an estimated $10.3M.

  • 103 institutional investors held Evofem Biosciences, Inc. Common Stock (EVFM) as of Q1 2021, up from 93 in Q4 2020.
  • Funds reported $74.5M of Evofem Biosciences, Inc. Common Stock stock for Q1 2021, down 6.8% quarter-over-quarter.
  • 31 funds opened new Evofem Biosciences, Inc. Common Stock positions in Q1 2021 and 18 closed out, a net change of +13 holders.
  • The largest Evofem Biosciences, Inc. Common Stock buyer in Q1 2021 was Maven Securities, an estimated $8.33M added.
  • The largest Evofem Biosciences, Inc. Common Stock seller in Q1 2021 was Invesco, an estimated $10.3M sold.

Based on aggregated 13F filings for Q1 2021.